Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0360319950270060929
Journal of Korean Cancer Research Association
1995 Volume.27 No. 6 p.929 ~ p.935
The Significaned of Serum CA 19-9 Level Change after Biliary Drainge Procedures in Pancreatic and Biliary Tract Cancer
±èÇö°¢
ÀÌâÈñ/·ù¹é·Ä/Á¤¼÷Çâ/±èÀ¯Ã¶/±èâ¹Î/ÀÌÁø¿À/°­Å¿õ/µµ¿µ¼ö
Abstract
Although CA 19-9 has been widely used as a tumor marker for the diagnosis of pancreatobiliary cancers, the pattern of CA 19-9 level change after biliary drainage has not been well characterized. Because biliary drainage procedures are frequently
employed for the temporary of palliative measures in biliary obstruction, the precise understanding on the change of CA 19-9 level after biliary drainage may be very helpful for the followup evaluation of those cases. We prospectively analyzed
the
serum
CA 19-9 level before and after percutaneous transhepatic biliary drainage (PTBD) and biliary stent in patients with pancreatic, biliary trach cancer and common bile duct stone.
Serum CA 19-9 level was initially measured by radioimmunoassay in 69 patients with bening and malignant pancreatobiliary diseases. In 22 of 69 patients, PTBD and/or the insertion of biliary stent were performed and seial checks of CA 19-9 levers
were
followed.
The elevation of serum CA 19-9 level was highly associated with pancreatobiliary cancers, especially in the cases with biliary obstruction, and in the CBD stones complicated with acute cholangitis. The serum CA 19-9 levels in most cases were
significantly decreased by PTBD. There was the trend that the decrease after PTBD in biliary tract cancer was more prominent than that of pancreatic cancer.
The elevation of serum CA 19-9 level was highly associated with the presence of biliary obstruction in pancreatobiliary cancer. Because the biliary drainage procedures significantly decrease serum CA 19-9 level, this can not be used for the
marker
of
cancer progression after biliary drainage procedures.
KEYWORD
FullTexts / Linksout information
 
Listed journal information
KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø